

IR Materials –Q1 FY3/26–

August 8, 2025

Nipro Corporation

Exchange rate, sensitivity / Product Category

<Average rate>

	FY2024				FY2025				
	Jan-Mar	Jan-Jun	Jan-Sep	Jan-Dec	Jan-Mar	Jan-Jun	Jan-Sep	Jan-Dec	Forecast
¥/USD	149.88	154.06	151.59	152.24	151.21	—	—	—	139.00
¥/EUR	162.15	166.12	164.61	164.36	159.35	—	—	—	158.00
¥/CNY	20.74	21.25	21.05	21.12	20.75	—	—	—	20.00

<Closing rate>

	FY2024 As of Mar.31	FY2024 As of Dec.30	FY2025 As of Mar.31	FY2025 As of Jun.30
¥/USD	151.41	161.07	149.52	144.81
¥/EUR	163.24	172.33	162.08	169.66
¥/CNY	20.83	22.04	20.59	20.19

<Estimates of Forex sensitivity>

¥100M	Net Sales	Operating Profit
¥/USD	10.2	0.5
¥/EUR	6.0	2.5
¥/CNY	18.3	9.0

<Product Category>

Medical devices	
Dialyzers	Dialyzers (artificial kidneys), HDF filters
Dialysis equipment	Dialysis systems, maintenance, dialysis equipment parts
Other dialysis-related products	Blood circuits, AVF needles, etc.
Needles	PSV needles, safetouch needles, etc.
Vascular products	Catheter sets for cardiovascular treatments, thrombus aspiration catheters, etc.
Infusion-related products	Infusion sets, IV cannulas, etc.
Testing products	Neotube (vacuum blood collection tube), etc.
Diabetes-related products	Insulin needles, blood glucose meters (for overseas markets), lancets
Surgical device-related products	Mechanical circulatory support, cardiopulmonary bypass products
Other products	Medical instruments, blood-related products, cell culture-related products, gloves, etc.

Pharmaceuticals	
Oral drugs	Oral drugs
Injection and infusion products	Syringe kits, vial formulations, dual chamber bags (PLW), powdered dialysate, dialysis fluids, etc.
External preparations and patches	External preparations, patches
Others, in vitro diagnostics, etc.	Reagents, pharmaceuticals, blood glucose meters, etc.

Pharma Packaging	
Glass tubing-related products	Medical-use glass tubing, non-medical use glass tubing, glass raw materials
Glass ampoules	Ampoules (single tip, double tip)
Glass vials	Vials (blowback, screw, sterilized, etc.)
Glass syringes	Syringes (luer lock, luer slip, sterilized, etc.)
Rubber stoppers and plugs	Rubber stoppers, plugs, closures, and caps
Plastic containers	Plastics
Thermos bottles	Glass for thermos bottles
Other products	Glass containers and others, special glass containers, cartridge glass and others, etc.

Table of Contents

Business Overview----- 4

Q1 FY3/26 Results----- 5

SG&A Expenses: Major Accounts----- 6

Research and Development Expenses----- 7

Capex and Depreciation----- 8

P/L comparison excluding forex impact----- 9

Segment Sales and Segment Profit-----10

(1) Medical-Related Segment Sales (Domestic)-----11

(1) Medical-Related Segment Sales (Overseas) -----12

(2) Pharmaceutical-Related Segment Sales -----13

(3) Pharma Packaging Segment Sales-----14

Net Sales by Segment and Product Category-----15

Net Sales by Segment and Region-----16

Net Sales by Product Category-----17,18

Business Overview

Manufacturing

The new installation of dialyzer lines (Odate, Akita) in FY03/26 is shown below.
The 11th line at the Odate, Akita Plant starts operation in April 2025, and the 7th line for FB dialyzers is scheduled to start operation in August 2025.

2025												2026			
1	2	3	4	5	6	7	8	9	10	11	12	1~3	4~6	7~9	10~12
			Odate Plant Dialyzers 11th line began operations				Odate Plant FB Dialyzers 7th line began operations						Vietnam Dialyzers 1st line will began operations		Vietnam Dialyzers 2nd line will began operations

Sales

Dialysis medical devices	Domestic sales remained flat compared to the previous year. For overseas sales, while Asia remained flat YoY, sales increased in the Americas due to continued stable orders for dialyzers and dialysis equipment, in Europe due to increased demand for dialyzers, and in China due to a recovery in demand for dialyzers.
Vascular-related products	Domestic sales recovered and increased due to expanded applications for drug-eluting balloons. In addition, sales increased due to strong performance of balloon catheters, which were launched in earnest last fiscal year. Overseas sales remained strong in Europe.
Pharmaceuticals (own brand)	Oral drugs increased in quantity due to an increase in the number of selected medical treatments, but decreased in sales due to falling drug prices. External preparations and patches decreased due to a decrease in supply. Injections increased due to strong shipments.
Pharmaceuticals (contract manufacturing)	Sales of GE products increased due to increased orders for mainstay anticancer drugs, despite the discontinuation of some commissioned products. Although sales of brand-name/long-listed products are experiencing a decline in orders due to the impact of selected medical treatments, existing items showed an increase due to price transfers and the start of deliveries of new orders.
Pharma Packaging	Domestic orders increased for infusion-related products and tubing, but amounts decreased for vials and tubing in the US and for sterile syringes in Europe, resulting in an overall decrease.

Q1 FY3/26 Results

					Quarterly Results				
	Q1 FY03/25	Q1 FY03/26	Change (Change %)	FY03/25 Forecast (Profit ratio)	FY03/25				FY03/26
					Q1	Q2	Q3	Q4	Q1
(¥ 100 million)									
Net sales	1,519.8	1,592.2	+72.3 +4.8%	6,770.0	1,519.8	1,600.3	1,672.6	1,653.0	1,592.2
Cost of sales	1,064.8	1,090.6	+25.7 +2.4%	4,710.0	1,064.8	1,111.8	1,158.8	1,201.4	1,090.6
Gross profit (※1)	459.0	501.5	+42.5	2,060.0	459.0	484.3	513.8	451.6	501.5
	30.2%	31.5%	+9.3%	30.4%	30.2%	30.3%	30.7%	27.3%	31.5%
SG&A expenses	401.1	429.4	+28.2	1,690.0	401.1	407.6	426.3	407.6	429.4
	26.4%	27.0%	+7.0%	25.0%	26.4%	25.5%	25.5%	24.7%	27.0%
Operating profit	57.8	72.1	+14.2	370.0	57.8	76.7	87.4	43.9	72.1
	3.8%	4.5%	+24.6%	5.5%	3.8%	4.8%	5.2%	2.7%	4.5%
Ordinary profit (※2)	64.2	35.1	-29.0	242.0	64.2	-19.2	95.1	-31.9	35.1
	4.2%	2.2%	-45.2%	3.6%	4.2%	-1.2%	5.7%	-1.9%	2.2%
Profit attributable to owners of parent	26.2	32.7	+6.4	129.5	26.2	-24.9	64.6	-14.8	32.7
	1.7%	2.1%	+24.5%	1.9%	1.7%	-1.6%	3.9%	-0.9%	2.1%

(*1) Effect of unrealized gains on gross profit
 Q1 FY03/25 -¥400 million
 Q1 FY03/26 -¥920 million

(*2) Foreign exchange gains
 Q1 FY03/25 +¥3,070 million
 Q1 FY03/26 -¥1,300 million

- Net sales

Net sales as a whole increased by ¥7,230 million YoY, due to strong sales of dialyzers in the Americas, Europe, and China in overseas medical-related businesses and increased sales of Insulin Needles and dialyzers in the B2B businesses.
- Gross profit

Gross profit as a whole increased by ¥4,250 million YoY, while labor costs increased, raw material costs were restrained.
- Operating profit

Operating profit increased by ¥1,420 million YoY, due to cost of sales (raw material costs) were restrained, while SG&A expenses increased due to higher labor costs both domestic and overseas, as well as higher transportation expenses in North, Central, and South America and Europe.
- Ordinary profit

Ordinary Profit decreased by ¥2,900 million YoY due to ¥1,300 million foreign exchange loss was recorded this fiscal year, whereas ¥3,070 million of foreign exchange gain was recorded in the previous fiscal year, resulting in a net deterioration of ¥4,370 million.
- Profit

Profit increased by ¥640 million YoY due to the transfer of land for the regenerative medicine research and manufacturing base (Tokyo CPF※) (facilities continue to be used under a lease agreement, with no change in operations) resulted in a gain on sale of fixed assets of ¥4,140 million. *CPF : Cell Processing Facility

SG&A Expenses: Major Accounts

	Q1 FY03/25	Q1 FY03/26		Change (Change %)	FY03/26 Forecast (Achievement %)
		Actual	% of Total		
(¥ 100 million)					
Personnel	129.6	142.3	33.2%	+12.7 +9.9%	565.3 25.2%
R&D (*1)	51.4	54.6	12.7%	+3.1 +6.2%	208.2 26.2%
Transportation	35.4	41.2	9.6%	+5.7 +16.2%	176.9 23.3%
Depreciation (*2)	37.2	36.0	8.4%	-1.1 -3.2%	155.1 23.2%
Commission expenses (*3)	23.6	25.9	6.0%	+2.3 +9.8%	109.7 23.6%
Promotion (*4)	24.8	24.9	5.8%	+0.0 +0.1%	84.1 29.6%
Travel & transportation	10.9	12.5	2.9%	+1.5 +14.3%	51.3 24.4%
Storage	9.5	10.0	2.3%	+0.5 +6.1%	39.0 25.8%
Others	78.4	81.7	19.0%	+3.2 +4.2%	300.4 27.2%
Total	401.1	429.4	100.0%	+28.2 +7.0%	1,690.0 25.4%

*1: R&D expenses, experimentation and research expenses, and development amortization
 *2: Depreciation, goodwill amortization
 *3: Commission expenses, consulting expenses
 *4: Sales commissions, samples, advertising, and entertainment expenses

- Personnel expenses | Personnel expenses increased by ¥1,270 million YoY due to increase in employees and base salary domestically and internationally.
- Transportation expenses | Overseas freight charges in North, Central, and South America and Europe increased by ¥570 million YoY.
- Others | Taxes and public dues increased by ¥830 million YoY due to increase in tax-exempt sales resulting from the transfer of land of Tokyo CPF. (as a whole ¥1,350 million in the current fiscal year, ¥520 million in the previous fiscal year)

R&D Expenses

	Q1 FY03/25	Q1 FY03/26	Change (Change %)	FY03/26 Forecast (Achievement %)
(¥ 100 million)				
Medical (*1)	33.0	36.1	+3.1 +9.6%	151.7 23.9%
Pharmaceutical (*1)	24.1	24.9	+0.7 +3.2%	91.1 27.4%
Pharma Packaging (*1)	1.4	1.2	-0.1 -13.0%	7.2 17.3%
Total (*2)	58.6	62.4	+3.7 +6.4%	250.0 25.0%

(*1) The aggregation method has been revised based on the definition of R&D expenses in the accounting standards.
 (*2) Including R&D expenses in manufacturing costs and SG&A Expenses.

Medical-Related | An increase of ¥310 million YoY due to outsourced development costs and Vascular product development and clinical trials.

Pharmaceutical-Related | An increase of ¥70 million YoY resulted from higher research-related personnel expenses and increased raw material costs caused by the weak yen and inflation, despite a decline in commissioned research expenses.

Pharma Packaging | Almost unchanged from the previous year.

Capex and Depreciation

	Capex				Depreciation			
	Q1 FY03/25	Q1 FY03/26	Change (Change %)	FY03/25 Forecast (Achievement %)	Q1 FY03/25	Q1 FY03/26	Change (Change %)	FY03/25 Forecast (Achievement %)
(¥ 100 million)								
Medical-Related	126.6	64.0	-62.5 -49.4%	336.2 19.1%	81.2	88.7	+7.5 +9.3%	388.0 22.9%
Pharmaceutical-Related	62.5	29.5	-33.0 -52.8%	257.2 11.5%	37.0	34.0	-3.0 -8.1%	143.9 23.7%
Pharma Packaging	20.2	11.3	-8.9 -44.0%	62.2 18.3%	17.8	14.6	-3.2 -18.0%	69.7 21.0%
Other	3.7	7.1	+3.3 +90.2%	51.6 13.9%	12.2	11.9	-0.2 -1.9%	47.6 25.2%
Total	213.2	112.1	-101.1 -47.4%	707.1 15.9%	148.3	149.4	+1.0 +0.7%	649.2 23.0%

Capex

Medical-related investments, in total of ¥6,400 million, included ¥650 million for the part of the restoration work at Odate Plant following a fire occurred in 2023, ¥1,310 million for dialysis-related equipment and building construction at Nipro Vietnam, and ¥640 million for equipment and supplies in the dialysis center at Nipro Medical Corporation. However, compared to the previous year, there was a decrease of ¥6,250 million due to the completion of dialyzer-related investments at the Odate Plant and Hefei Plant in the previous fiscal year. Pharmaceutical-related investments included ¥1,490 million for the general pharmaceutical building at Nipro Pharma’s Omi Plant and ¥280 million for the expansion of the Ise Plant. However, due to expansion investments at the Omi Plant in the previous fiscal year, there was a decrease of ¥3,300 million compared to the previous year. Pharma Packaging investments, in total of ¥1,130 million, included ¥370 million in equipment investment in France, ¥260 million in capacity expansion in Germany, and ¥220 million in renovation investment in the U.S.. However, due to expansion investments in the U.S. in the previous fiscal year, there was a decrease of ¥890 million yen compared to the previous year. Other items included one-time renewal costs for PC leases, resulting in an increase of ¥330 million compared to the previous year.

Depreciation

Although medical-related depreciation increased due to the establishment of a new seventh factory at the Odate Plant, depreciation expenses remained at the same level as the previous year due to a decrease in depreciation of Nipro Pharma's machinery and equipment related to pharmaceuticals, as well as impairment losses at Pharma Packaging in France.


P/L comparison excluding forex impact

	Q1 FY03/25	Q1 FY03/26	Exchange rate Impact*	FY03/26 Results Excl. Impact	Change %
(¥ 100 million)	【a】	【b】	【c】	【d=b-c】	【d÷a】
Net sales	1,519.8	1,592.2	-5.1	1,597.3	+5.1%
Cost of sales	1,064.8	1,090.6	+6.2	1,084.4	
Gross profit	459.0	501.5	-11.3	512.9	+11.7%
(%)	30.2%	31.5%		32.1%	
SG&A expenses	401.1	429.4	-1.5	430.9	
Operating profit	57.8	72.1	-9.8	81.9	+41.6%
(%)	3.8%	4.5%		5.1%	
Non-operating income	40.8	13.8		13.8	
Non-operating expenses	34.5	50.8	+43.8	7.0	
Ordinary profit	64.2	35.1	-53.6	88.8	+38.3%
Extraordinary income	0.4	41.8		41.8	
Extraordinary losses	3.4	0.8		0.8	
Profit before tax	61.2	76.1	-53.6	129.7	+111.9%
Income taxes	31.0	38.0	-26.8	64.8	
Profit attributable to non-controlling interests	3.9	5.3		5.3	
Profit attributable to owners of parent	26.2	32.7	-26.8	59.5	+126.7%

* Total foreign currency transactions converted to yen using the difference from previous year's rate.
Forex impact on yen-denominated transactions has not been taken into account.

Segment Sales and Segment Profit

	Net sales				Segment Profit			
	Q1 FY03/25	Q1 FY03/26	Change (Change %)	FY03/26 Forecast (Achievement %)	Q1 FY03/25	Q1 FY03/26	Change (Change %)	FY03/26 Forecast (Profit ratio)
(¥ 100 million)								
Medical-Related segment	1,178.8	1,263.8	+85.0 +7.2%	5,334.2 23.7%	116.5	122.8	+6.2 +5.4%	533.9 10.0%
Pharmaceutical-Related segment	180.5	191.8	+11.2 +6.2%	863.7 22.2%	8.7	32.2	+23.4 +268.6%	107.8 12.5%
Pharma Packaging segment	158.5	134.0	-24.4 -15.4%	568.0 23.6%	5.1	0.6	-4.5 -88.2%	3.5 0.6%



- Medical-Related segment

Segment profit increased by ¥620 million YoY due to the containment of raw material costs and strong sales of medical equipment overseas, although depreciation and amortization expenses, personnel expenses, and transportation expenses increased.
- Pharmaceutical-Related segment


Segment profit increased by ¥2,340 million YoY, mainly due to new orders for oral drugs, increased shipments of anticancer drugs, and a revision of inventory valuation at the beginning of the fiscal year.
- Pharma Packaging segment

Segment profit decreased by ¥450 million YoY due to a decline in sales.

(1) Medical-Related Segment Sales (Domestic)

Net sales	Q1	Q1	Change	FY03/26
(¥ 100 million)	FY03/25	FY03/26	(Change %)	Forecast (Achievement %)
Domestic business	551.8	553.5	+1.6 +0.3%	2,439.8 22.7%
Medical devices	280.6	280.7	+0.0 +0.0%	1,261.7 22.2%
Pharmaceuticals	271.2	272.8	+1.5 +0.6%	1,178.1 23.2%

Quarterly Sales Trends
(¥ 100 million)



Medical devices

Sales of dialyzers decreased by ¥300 million due to a decrease in sales volume due to limited shipments of Fainflux.

Sales of dialysis equipment decreased by ¥430 million YoY due to a decrease in shipments.

In the field of injection needles and infusion-related products, sales of injection needles increased by ¥320 million YoY due to price increases, and sales of infusion-related products increased by ¥210 million YoY.

Sales of vascular-related products increased by ¥1,400 million YoY and recovered steadily, as in the previous year, due to the expansion of applications for drug-eluting balloons. In addition, sales of balloon catheter products, which were launched in earnest last year, progressed steadily.

Pharmaceuticals


Sales volume of oral drugs increased due to the promotion of switching to GE products through selected medical treatments, but continued price declines for drugs including Nexium AG impacted, resulting in YoY decrease of ¥290 million.

Sales of injectable and infusion medications increased by ¥1,110 YoY due to continued strong shipments of Pegfilgrastim BS, which suppresses the onset of febrile neutropenia caused by cancer chemotherapy.

External preparations and patches decreased by ¥620 million YoY due to a decline in shipments of Budesonide inhalation powder and Loxoprofen tape.

(1) Medical-Related Segment Sales (Overseas)

Net sales	Q1	Q1	Change	FY03/26
(¥ 100 million)	FY03/25	FY03/26	(Change %)	Forecast (Achievement %)
Overseas business	626.9	710.3	+83.4 +13.3%	2,894.1 24.5%
B2B (other brands)	81.8	91.2	+9.4 +11.5%	355.9 25.6%
Nipro brands	545.1	619.1	+74.0 +13.6%	2,538.2 24.4%
Americas	223.6	277.3	+53.7 +24.0%	1,060.1 26.2%
Europe	122.8	131.1	+8.2 +6.7%	562.1 23.3%
Asia	118.2	119.9	+1.7 +1.4%	536.2 22.4%
China	80.3	90.6	+10.2 +12.8%	379.8 23.9%



B2B

Sales increased by ¥940 million YoY due to strong sales of Insulin Needles in Europe due to higher demand for GLP-1 and strong sales of SafeTouch PSV in the Americas.

Nipro brand

Americas

Sales in the Americas increased by ¥5,370 million YoY. Reasons are as follows: Sales of Dialyzer, dialysis machine, injectable and infusion medications increased by ¥3,930 million due to reasons such as large contracts. In addition, sales at dialysis centers were strong due to an increase in the number of patients in Guatemala and Ecuador and the expansion of dialysis centers in Peru. Also, in North America, demand for Blood Tubing Sets increased due to supply shortages at competitors, and sales of SafeTouch PSV were strong.

Europe

Sales in Europe increased by ¥820 million YoY due to strong sales of vascular-related products and increased demand for dialyzers.

Asia

Sales in Asia increased by ¥170 million YoY. Reasons are as follows: Sales of dialysis machines in India and Saudi Arabia decreased by ¥960 million as a reaction to large tender activities in the last year. On the other hand, sales of dialyzers increased by ¥510 million due to tender activities in Saudi Arabia. In addition, sales of dialysis machine increased by ¥420 million due to higher demands in Vietnam, Indonesia, and Philippines. The expansion of dialysis centers in Thailand and increased demand for Injection Needles in Malaysia also contributed to stronger sales in Asia.


China

Sales in China increased by ¥1,020 million YoY due to the start of centralized procurement and the recovery in demand of dialyzers. In addition, sales at dialysis centers remained strong due to an increase in the number of patients and the expansion of dialysis centers.

(2) Pharmaceutical-Related Segment Sales

Net sales	Q1	Q1	Change	FY03/26
(¥ 100 million)	FY03/25	FY03/26	(Change %)	Forecast (Achievement %)
Pharmaceutical-Related	180.5	191.8	+11.2 +6.2%	863.7 22.2%
Generic drugs	73.4	82.3	+8.9 +12.2%	318.7 25.9%
Brand-name drugs	77.0	83.8	+6.8	430.6
Long-listed drugs			+8.9%	19.5%
OTC drugs	11.0	6.8	-4.1	37.5
Active ingredients, etc.			-37.9%	18.2%
JMI Pharma	19.1	18.7	-0.3	76.9
			-2.0%	24.4%

Quarterly Sales Trends



Generic drugs

Sales of injections increased by ¥1,310 million YoY due to an increase in orders of main anticancer drugs.

Sales of oral drugs fell ¥130 million YoY due to a decline in orders.

Sales of external preparations fell ¥290 million YoY due to discontinuation of commissioned products.

Brand-name/long-listed drugs

Sales of injections increased by ¥1,300 million YoY due to an increase in orders for new commissioned products, as well as existing products, and implemented price increases.

Sales of oral drugs fell ¥130 million YoY due to a decrease in orders due to the impact of selected medical treatments.

Sales of external preparations fell ¥480 million YoY due to a decline in orders.


OTC drugs, active ingredients, etc.

Sales fell ¥410 million YoY due to a decline in orders for OTC external preparations scheduled to be discontinued commission.

(3) Pharma Packaging Segment Sales

Net sales	Q1	Q1	Change	FY03/26
(¥ 100 million)	FY03/25	FY03/26	(Change %)	Forecast (Achievement %)
Pharma Packaging	158.5	134.0	-24.4 -15.4%	567.9 23.6%
Japan	37.1	38.6	+1.4 +4.0%	145.9 26.5%
Overseas	121.3	95.4	-25.9 -21.4%	422.0 22.6%
Europe	72.9	61.6	-11.3 -15.5%	286.5 21.5%
United States	35.8	25.6	-10.1 -28.4%	117.1 21.9%
China	7.3	4.6	-2.6 -36.5%	4.3 108.8%
India	5.2	3.4	-1.7 -33.3%	13.9 25.1%

Quarterly Sales Trends



Japan

Sales of infusion-related products and glass vials increased due to the shipment adjustment originally scheduled for the fourth quarter of 2024. Sales of glass tubing decreased temporarily after the price revision in October 2024, but orders are expected to recover from 2025 onwards.

Overall, sales increased by ¥140 million YoY.

Overseas

Europe

Sales decreased by ¥1,130 million YoY mainly due to sterilized glass syringes, which performed well last fiscal year, decreased due to temporary equipment maintenance, and the new entrants to the market impacted.

United States

Sales of glass tubing increased by ¥60 million YoY due to strong demand related to biopharmaceuticals.
Sales of glass vials decreased by ¥1,080 million YoY due to inventory adjustments on glass containers global market.

Net Sales by Segment and Product Category

Segment		Medical	Pharmaceutical	Pharma	Other	Total
Product	(¥ 100 million)	-Related	-Related	Packaging		
Medical devices	Q1 FY03/26	947.8	-	(*3) 11.9	-	959.8
	Q1 FY03/25	871.3	-	(*3) 11.5	-	882.8
Pharmaceuticals	Q1 FY03/26(*1)	315.9	(*2) 191.8	1.8	-	509.6
	Q1 FY03/25(*1)	306.6	(*2) 180.5	1.3	-	488.4
Pharma Packaging	Q1 FY03/26	-	-	119.9	-	119.9
	Q1 FY03/25	0.7	-	145.3	-	146.1
Other	Q1 FY03/26	0.0	-	0.2	2.3	2.7
	Q1 FY03/25	0.0	-	0.3	1.8	2.3
Total	Q1 FY03/26	1,263.8	191.8	134.0	2.3	1,592.2
	Q1 FY03/25	1,178.8	180.5	158.5	1.8	1,519.8

*1: In-house generic drugs
 *2: Contract manufacturing of pharmaceuticals
 *3: Needles, infusion-related products, testing products

Net Sales by Segment and Region

Region		Medical -Related	Pharmaceutical -Related	Pharma Packaging	Other	Total
(¥ 100 million)						
Japan	Q1 FY03/26	555.0	170.9	38.7	2.3	767.1
	Q1 FY03/25	552.1	159.9	37.2	1.8	751.2
Overseas Total	Q1 FY03/26	708.8	20.9	95.3	0.0	825.0
	Q1 FY03/25	626.6	20.5	121.2	-	768.5
Americas	Q1 FY03/26	305.9	-	25.3	0.0	331.3
	Q1 FY03/25	247.8	-	35.2	-	283.1
Europe	Q1 FY03/26	163.0	1.7	61.5	-	226.3
	Q1 FY03/25	151.5	0.6	72.0	-	224.2
China	Q1 FY03/26	91.1	0.1	4.7	-	95.9
	Q1 FY03/25	82.0	0.1	7.3	-	89.5
Asia Other	Q1 FY03/26	148.6	19.0	3.7	-	171.4
	Q1 FY03/25	145.1	19.8	6.6	0.0	171.6
Total	Q1 FY03/26	1,263.8	191.8	134.0	2.3	1,592.2
	Q1 FY03/25	1,178.8	180.5	158.5	1.8	1,519.8

Net Sales by Product Category (1)

Business Category		Overall				Overseas				Japan			
		Q1 FY03/25	Q1 FY03/26	Change	Change %	Q1 FY03/25	Q1 FY03/26	Change	Change %	Q1 FY03/25	Q1 FY03/26	Change	Change %
(¥ 100 million)													
Medical devices	Dialyzers	245.7	282.5	+36.8	+15.0%	189.5	229.3	+39.8	+21.0%	56.2	53.1	-3.0	-5.4%
	Dialysis equipment	72.9	72.0	-0.9	-1.2%	56.7	60.1	+3.3	+5.9%	16.2	11.9	-4.2	-26.4%
	Other dialysis-related products	141.0	157.1	+16.1	+11.5%	120.1	135.8	+15.6	+13.0%	20.8	21.3	+0.5	+2.5%
	Dialysis-related products total	459.7	511.8	+52.0	+11.3%	366.4	425.3	+58.8	+16.1%	93.2	86.5	-6.7	-7.3%
	Needles *	130.5	157.7	+27.1	+20.8%	86.2	108.1	+21.8	+25.4%	44.2	49.5	+5.2	+11.9%
	Vascular products	83.1	87.3	+4.1	+5.0%	21.3	24.1	+2.8	+13.5%	61.8	63.1	+1.2	+2.1%
	Infusion-related products	57.3	59.7	+2.3	+4.2%	24.6	24.9	+0.2	+1.1%	32.7	34.8	+2.1	+6.5%
	Testing products *	29.8	18.3	-11.4	-38.4%	20.2	9.3	-10.8	-53.8%	9.6	9.0	-0.5	-6.1%
	Diabetes-related products	30.0	32.2	+2.2	+7.3%	27.0	28.4	+1.4	+5.3%	3.0	3.8	+0.7	+25.7%
	Surgical device-related products	23.8	24.4	+0.6	+2.7%	5.0	6.3	+1.2	+25.6%	18.7	18.1	-0.6	-3.4%
	Other products	66.9	66.6	-0.3	-0.5%	39.4	38.8	-0.5	-1.3%	27.5	27.7	+0.1	+0.7%
	Category Total	881.6	958.5	+76.8	+8.7%	590.4	665.6	+75.2	+12.7%	291.2	292.8	+1.6	+0.6%
Pharmaceuticals (own brand)	Oral drugs	119.8	117.1	-2.6	-2.2%	-	0.1	+0.1	-	119.8	117.0	-2.8	-2.4%
	Injection and infusion products	143.0	162.0	+18.9	+13.2%	34.4	42.3	+7.8	+22.8%	108.6	119.7	+11.1	+10.2%
	External preparations and patches	18.1	11.8	-6.2	-34.5%	-	-	-	-	18.1	11.8	-6.2	-34.5%
	Others, in vitro diagnostics, etc.	25.5	24.8	-0.6	-2.6%	0.9	0.6	-0.2	-26.6%	24.6	24.2	-0.4	-1.6%
	Category Total	306.6	315.9	+9.3	+3.1%	35.4	43.1	+7.7	+21.9%	271.1	272.7	+1.6	+0.6%
Regenerative medicines	Regenerative medicine products	1.2	1.2	+0.0	+3.8%	-	-	-	-	1.2	1.2	+0.0	+3.8%

* Phlebotomy needles etc. included in “testing products” have been changed to “Needles.” from this fiscal year.

Net Sales by Product Category (2)

Business Category		Overall				Overseas				Japan			
		Q1 FY03/25	Q1 FY03/26	Change	Change %	Q1 FY03/25	Q1 FY03/26	Change	Change %	Q1 FY03/25	Q1 FY03/26	Change	Change %
(¥ 100 million)													
Pharmaceuticals (contract manufacturing)	Oral drugs	66.4	63.2	-3.2	-4.8%	0.1	0.2	+0.0	+5.7%	66.2	63.0	-3.2	-4.9%
	Injection and infusion products	72.5	99.4	+26.8	+36.9%	0.9	1.4	+0.4	+45.0%	71.6	97.9	+26.3	+36.8%
	External preparations and patches	18.0	7.4	-10.5	-58.7%	0.1	0.3	+0.1	+104.7%	17.8	7.1	-10.7	-60.1%
	Others, in vitro diagnostics, etc.	5.7	4.8	-0.8	-14.8%	+0.1	0.2	+0.0	-	5.5	4.5	-0.9	-17.0%
	Category Total	162.7	174.9	+12.1	+7.5%	1.4	2.1	+0.7	+47.3%	161.2	172.7	+11.4	+7.1%
Pharmaceuticals (JMI Pharma)	Oral drugs	18.9	18.5	-0.4	-2.2%	18.9	18.5	-0.4	-2.2%	-	-	-	-
	Injection and infusion products	0.1	0.1	+0.0	+27.1%	0.1	0.1	+0.0	+27.1%	-	-	-	-
	Category Total	19.1	18.7	-0.3	-2.0%	19.1	18.7	-0.3	-2.0%	-	-	-	-
Pharma Packaging	Glass tubig-related products	35.2	33.1	-2.1	-6.0%	29.1	26.2	-2.9	-10.0%	6.0	6.8	+0.7	+12.9%
	Glass ampoules	23.4	18.4	-5.0	-21.3%	23.4	18.4	-5.0	-21.4%	0.0	0.0	+0.0	+4.4%
	Glass vials	44.9	31.1	-13.8	-30.7%	39.4	24.6	-14.8	-37.6%	5.4	6.5	+1.0	+18.7%
	Glass syringes	24.2	19.5	-4.6	-19.2%	24.1	19.4	-4.6	-19.3%	0.0	0.0	+0.0	+22.4%
	Rubber stoppers and plugs	3.5	3.7	+0.1	+5.1%	-	0.0	+0.0	-	3.5	3.7	+0.1	+3.9%
	Plastic containers	5.5	4.6	-0.9	-16.4%	0.0	-	+0.0	-100.0%	5.5	4.6	-0.9	-16.4%
	Thermos bottles	1.3	1.5	+0.1	+10.9%	-	-	-	-	1.3	1.5	+0.1	+10.9%
	Other products	7.7	7.7	+0.0	+0.3%	5.6	6.3	+0.6	+11.7%	2.0	1.4	-0.6	-31.0%
	Category Total	146.1	119.9	-26.1	-17.9%	121.8	95.1	-26.7	-21.9%	24.2	24.8	+0.5	+2.3%
Other	Sales of production machinery and real estate leasing	2.3	2.7	+0.4	+18.6%	0.2	0.1	+0.0	-22.0%	2.0	2.5	+0.4	+23.2%
Consolidated Total		1,519.8	1,592.1	+72.3	+4.8%	768.5	825.0	+56.5	+7.4%	751.2	767.0	+15.8	+2.1%

Forecasts and other forward-looking statements in this document are based on information currently available to the Company and certain assumptions that the Company believes to be reasonable.

Actual results may differ materially from those described in this document due to various factors that may arise in the future.

This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



NIPRO

Live Longer. Live Better.